-
Prothena Plummets 60% After Lead Drug Fails Phase 2 Trial
Monday, April 23, 2018 - 9:39am | 381Read More...Prothena Corporation PLC (NASDAQ: PRTA) plummeted 60 percent Monday morning after a disappointing update relating to the company's treatment for AL amyloidosis. What Happened Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan...
